(Q44263661)

English

CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

based on heuristic

inferred from title

3

object named as

Ronald N Jones

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Alan H Mutnick

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Jeffrey T Kirby

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

CANCER Study Group

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

47-56

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Surveillance of antimicrobial resistance--what, how and whither?

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Infections caused by viridans streptococci in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Hospital-acquired infections: diseases with increasingly limited therapies

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Extended-spectrum beta-lactamase in Proteus mirabilis.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Persistent fever in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Identifiers

10.1345/APH.1C292

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44263661&oldid=2108985502"